Heterogeneity of hypoxic Ca2+ release in pulmonary and *

肺和 * 中缺氧 Ca2 释放的异质性

基本信息

  • 批准号:
    6927284
  • 负责人:
  • 金额:
    $ 39.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-19 至 2007-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hypoxia induces [Ca2+]I increase and associated vasoconstriction in pulmonary artery smooth muscle cells (PASMCs), but not in systemic artery myocytes. Futhermore, hypoxic Ca2+ and contractile responses are much greater in resistance than conduit PASMCs. However, very little is known about the cellular and molecular mechanisms underlying these functional differences. We and other investigators have consistently demonstrated that ryanodine receptor (RyR) Ca2+ release is critical for hypoxic [Ca2+]I increase and associated vasoconstriction in PASMCs. Our preliminary studies, together with previous findings, suggest that specific RyR subtypes (RyR1, RyR2 and RyR3) are differentially expressed in the vasculature. This heterogeneous nature of expression may contribute to observed differences in excitation-contraction coupling and hypoxic Ca2+ and contractile responses in various blood vessels. In addition, specific interactions of endogenous regulatory molecules FKBP12.6 (RyR inhibitor) and cADPR (RyR activator with distinct RyR subtypes may also play an important role in the heterogeneity of physiological and hypoxic Ca2+ release and vasoconstriction. To address these hypotheses, this proposal seeks to examine the following three questions (Specific Aims): Are RyR subtypes heterogeneously expressed in resistance and conduit pulmonary and mesenteric artery SMCs? 2) Is RyR Ca2+ release heterogeneous in resistance and conduit pulmonary and mesenteric artery SMCs? 3) Do the heterogeneities of RyR subtypes expression and RyR coupling to FKBP12.6 and cADPR explain differences in hypoxic Ca2+ release between resistance and conduit pulmonary and mesenteric artery SMCs? These aims will be pursued by using the state-of-the-art biophysical (confocal microscopy, patch clamp, etc), molecular and genetic approaches (gene knockout and over-expression). Thus, the findings from this proposal will extend our understanding of the cellular and molecular mechanisms that contribute to the differences and heterogeneity of physiological and hypoxic Ca2+ and contractile responses, and may identify novel therapeutic targets for pulmonary hypertension. The proposed studies are also of fundamental physiological significance with respect to the regulation of Ca2+ release in other cell types.
描述(由申请人提供): 低氧可引起肺动脉平滑肌细胞(PASMCs)[Ca~(2+)]i升高及相应的血管收缩反应,但对体动脉肌细胞无明显影响。此外,低氧钙离子和收缩反应的阻力比导管PASMCs大得多。然而,人们对这些功能差异背后的细胞和分子机制知之甚少。我们和其他研究人员一直证明,Ryanodine受体(RyR)钙释放在PASMCs缺氧性[Ca2+]i增加和相关的血管收缩中起关键作用。我们的初步研究结合以前的发现表明,特定的RyR亚型(RyR1、RyR2和RyR3)在血管系统中有不同的表达。这种表达的异质性可能有助于观察到不同血管中兴奋-收缩偶联以及低氧钙和收缩反应的差异。此外,内源性调节分子FKBP12.6(RyR抑制物)和cADPR(RyR激活剂)与不同RyR亚型的特异性相互作用也可能在生理性和缺氧性钙释放和血管收缩的异质性中发挥重要作用。为了解决这些假说,本研究试图检验以下三个问题(具体目的):RyR亚型在阻力和导管肺和肠系膜动脉SMC中是否异质性表达?2)RyR钙释放在阻力和管道性肺和肠系膜动脉SMC中是否异质性?3)RyR亚型表达和RyR偶联FKBP12.6和cADPR的异质性是否解释了阻力和管道性肺和肠系膜动脉SMC之间低氧钙释放的差异?这些目标将通过使用最先进的生物物理学(共聚焦显微镜、膜片钳等)、分子和遗传方法(基因敲除和过度表达)来实现。因此,这一研究结果将扩大我们对生理和低氧钙及收缩反应差异和异质性的细胞和分子机制的理解,并可能确定新的治疗肺动脉高压的靶点。这些研究对于调节其他类型细胞的钙释放也具有重要的生理学意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YONG-XIAO WANG其他文献

YONG-XIAO WANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YONG-XIAO WANG', 18)}}的其他基金

Cerebral vascular calcium signaling in diabetic Alzheimer's disease-related dementias
糖尿病阿尔茨海默病相关痴呆的脑血管钙信号传导
  • 批准号:
    10117843
  • 财政年份:
    2021
  • 资助金额:
    $ 39.5万
  • 项目类别:
Novel signaling in chronic hypoxic responses in pulmonary arteries
肺动脉慢性缺氧反应的新信号传导
  • 批准号:
    9186562
  • 财政年份:
    2014
  • 资助金额:
    $ 39.5万
  • 项目类别:
Novel signaling in chronic hypoxic responses in pulmonary arteries
肺动脉慢性缺氧反应的新信号传导
  • 批准号:
    8979717
  • 财政年份:
    2014
  • 资助金额:
    $ 39.5万
  • 项目类别:
Novel signaling in chronic hypoxic responses in pulmonary arteries
肺动脉慢性缺氧反应的新信号传导
  • 批准号:
    8825232
  • 财政年份:
    2014
  • 资助金额:
    $ 39.5万
  • 项目类别:
Signaling Mechanisms for Hypoxic Pulmonary Vasoconstriction
缺氧肺血管收缩的信号机制
  • 批准号:
    8389620
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
Signaling Mechanisms for Hypoxic Pulmonary Vasoconstriction
缺氧肺血管收缩的信号机制
  • 批准号:
    8598510
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
Signaling Mechanisms for Hypoxic Pulmonary Vasoconstriction
缺氧肺血管收缩的信号机制
  • 批准号:
    8237425
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
Signaling Mechanisms for Hypoxic Pulmonary Vasoconstriction
缺氧肺血管收缩的信号机制
  • 批准号:
    8882527
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
Mechanisms for hypoxic Ca2+ release in pulmonary artery myocytes
肺动脉肌细胞缺氧释放Ca2+的机制
  • 批准号:
    7839422
  • 财政年份:
    2009
  • 资助金额:
    $ 39.5万
  • 项目类别:
Heterogeneity of hypoxic Ca2+ release in pulmonary and *
肺和 * 中缺氧 Ca2 释放的异质性
  • 批准号:
    7104320
  • 财政年份:
    2003
  • 资助金额:
    $ 39.5万
  • 项目类别:

相似海外基金

L-type Calcium Channel SNP rs1006737: characterizing the genetic risks in MUD (Methamphetamine Use Disorder)
L 型钙通道 SNP rs1006737:表征 MUD(甲基苯丙胺使用障碍)的遗传风险
  • 批准号:
    10668210
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma
开发治疗哮喘的新型钙通道疗法
  • 批准号:
    10603554
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
开发一种治疗阿片类药物使用障碍的新型钙通道疗法
  • 批准号:
    10684558
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
使用 T 型钙通道和可溶性环氧化物水解酶的活性 IND 双重抑制剂开发治疗酒精使用障碍的新型药物
  • 批准号:
    10815882
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Novel Tools to Probe Trafficking and Function of Calcium Channel Signaling Complexes in Heart
探测心脏钙通道信号复合物的运输和功能的新工具
  • 批准号:
    10628914
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Mechanisms of L-type Calcium Channel Regulation in Heart Health and Disease
L 型钙通道在心脏健康和疾病中的调节机制
  • 批准号:
    10734121
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Structure-Function of Calcium Channel Complexes in Cardiac Physiology and Disease
钙通道复合物在心脏生理和疾病中的结构-功能
  • 批准号:
    10628911
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Research Initiation Award: Defining the role of DJ-1 in regulating L-type voltage-dependent calcium channel expression in neuronal plasticity
研究启动奖:定义 DJ-1 在调节神经元可塑性中 L 型电压依赖性钙通道表达中的作用
  • 批准号:
    2200474
  • 财政年份:
    2022
  • 资助金额:
    $ 39.5万
  • 项目类别:
    Standard Grant
Design and Preclinical Development of First-in-Class Selective T-type Calcium Channel Blockers for Chronic Pain
用于治疗慢性疼痛的一流选择性 T 型钙通道阻滞剂的设计和临床前开发
  • 批准号:
    452107
  • 财政年份:
    2021
  • 资助金额:
    $ 39.5万
  • 项目类别:
    Operating Grants
Preventing the Calcium Channel Blocker – Lower Extremity Edema – Loop Diuretic Prescribing Cascade in Older Adults
预防钙通道阻滞剂 – 下肢水肿 – 老年人袢利尿剂处方级联
  • 批准号:
    10399417
  • 财政年份:
    2021
  • 资助金额:
    $ 39.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了